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Abstract
Background: Cardiac stem cells (CSCs) promote myocardial recovery following ischemia through their regenerative
properties. However, little is known regarding the implication of paracrine action by CSCs in the setting of myocardial
ischemia/reperfusion (I/R) injury although it is well documented that non-cardiac stem cells mediate cardioprotection via
the production of paracrine protective factors. Here, we studied whether CSCs could initiate acute protection following
global myocardial I/R via paracrine effect and what component from CSCs is critical to this protection.
Methodology/Principal Findings: A murine model of global myocardial I/R was utilized to investigate paracrine effect of
Sca-1+ CSCs on cardiac function. Intracoronary delivery of CSCs or CSC conditioned medium (CSC CM) prior to ischemia
significantly improved myocardial function following I/R. siRNA targeting of VEGF in CSCs did not affect CSC-preserved
myocardial function in response to I/R injury. However, differentiation of CSCs to cardiomyocytes (DCSCs) abolished this
protection. Through direct comparison of the protein expression profiles of CSCs and DCSCs, SDF-1 was identified as one of
the dominant paracrine factors secreted by CSCs. Blockade of the SDF-1 receptor by AMD3100 or downregulated SDF-1
expression in CSCs by specific SDF-1 siRNA dramatically impaired CSC-induced improvement in cardiac function and
increased myocardial damage following I/R. Of note, CSC treatment increased myocardial STAT3 activation after I/R, whereas
downregulation of SDF-1 action by blockade of the SDF-1 receptor or SDF-1 siRNA transfection abolished CSC-induced
STAT3 activation. In addition, inhibition of STAT3 activation attenuated CSC-mediated cardioprotection following I/R. Finally,
post-ischemic infusion of CSC CM was shown to significantly protect I/R-caused myocardial dysfunction.
Conclusions/Significance: This study suggests that CSCs acutely improve post-ischemic myocardial function through
paracrine factor SDF-1 and up-regulated myocardial STAT3 activation.
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Introduction
Despite advances in the treatment of myocardial infarction (MI),
ischemic heart disease remains a leading cause of death world-
wide. MI causes an irreversible loss of myocardium followed by the
replacement of scar tissue. Stem cell-based therapy, therefore,
holds tremendous promise in the treatment of myocardial ischemia
due to their regeneration potential. However, accumulated
evidence has demonstrated that cardiac and vascular differentia-
tion of implanted cells plays a less important role in mediating
cardioprotection than previously thought. More and more studies
have pointed out that stem cells mediate their beneficial effects
mainly through production of paracrine factors [1–5]. Stem cell-
secreted protective molecules have been reported to increase cell
survival, reduce inflammation, promote local angiogenesis and
improve myocardial function after MI [1–4]. Studies from our
group have also demonstrated that infusion of mesenchymal stem
cells (MSCs) into isolated rodent hearts prior to ischemia improved
myocardial function after 25-minute ischemia followed by 40-
minutes reperfusion, clearly indicating that MSCs acutely protect
the heart without cell differentiation [5–7].
On the other hand, compelling evidence has suggested that the
adult heart contains cardiac stem cells (CSCs), which have been
isolated in many species based on stem cell markers such as Sca-1,
c-Kit, Isl-1, and/or MDR1 [8–17]. Prior research has primarily
focused on investigating the differentiation capacities of CSCs and
their ability to differentiate into cardiomyocytes, smooth muscle
cells and endothelial cells after MI [8,12,14,15]. However, little
information exists regarding the paracrine action of CSCs in
cardioprotection following myocardial ischemia/reperfusion (I/R)
injury. In fact, CSCs are capable of producing substantial
quantities of paracrine molecules [18–20]. Therefore, understand-
ing CSC-derived paracrine action is of value to promote protective
effect following myocardial ischemia. To date, although a majority
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VEGF, HGF and IGF-1 are able to protect the myocardium
against ischemic injury, it is largely unknown what component
derived from CSCs contributes to the improvement of cardiac
function in response to myocardial I/R injury.
Therefore, to determine the role of CSC-derived paracrine
action in modulating acute cardioprotection following I/R, we
utilized an isolated heart perfusion system (Langendorff) which
excludes the effects of other blood-borne elements on the actions
of CSCs and avoids the potential confounding effects of systemic
actions when the heart is subjected to I/R in vivo. In the present
study, we reported that intracoronary delivery of in-vitro
expanded Sca-1+ CSCs into isolated mouse hearts prior to
ischemia improved myocardial function following I/R injury. In
addition, the stromal-cell derived factor-1a (SDF-1) was identified
as one of the dominant paracrine factors secreted by CSCs.
Furthermore, we demonstrated that SDF-1 played a critical role in
CSC-mediated acute cardioprotection through the signal trans-
ducer and activator of transcription 3 (STAT3) signaling.
Results
Cardiac stem cell characteristics
In order to identify whether the cells we isolated from murine
hearts had cardiac stem cell characteristics, we first determined the
expression of stem cell markers. Flow cytometric data revealed that
these cells were positive for Sca-1 (.98%), CD29 (.98%) and
CD44 (,90%), but negative for hematopoietic stem cell markers
CD34, CD45 and the endothelial marker CD31, as well as CD117
(Fig. 1A). CSCs expressed similar levels of stem cell markers as
MSCs did (Fig. 1B). However, RT-qPCR analysis indicated that
CSCs exhibited much higher transcription levels of the cardiac
specific transcription factors NKX2.5, Gata4, MEF2c and Tbx5
compared to MSCs (Fig. 1C).
CSCs improved myocardial function through paracrine
action following I/R
Studies from our group and others have demonstrated that
implanted MSCs improved myocardial function after ischemic
injury through the release of protective factors [1,2,5,6]. To
investigate the paracrine effect of CSCs on cardiac function, we
infused CSCs (0.1610
6 in 1 ml of perfusate) into isolated mouse
hearts prior to ischemia through intracoronary delivery. Expect-
edly, infusion of MSCs acutely protected post-ischemic myocardial
function, which was in agreement with our previous observations
[5–7]. Importantly, significantly improved myocardial function of
LVDP and +/2 dP/dt was noticed in the CSC-pretreated group
compared to vehicle after I/R (Fig. 2A, B), suggesting that CSCs
are able to mediate acute cardioprotection following I/R like
MSCs did. To verify that CSC-derived paracrine factors are
responsible for this acute protection, we collected conditioned
medium (CM) from CSC culture and injected them into isolated
hearts. Similarly, infusion of CSC CM prior to ischemia improved
post-ischemic myocardial function of LVDP and +/2 dP/dt
Figure 1. Identification of cardiac stem cell (CSC) characteristics. A, Flow cytometry assay indicated expression of cell surface markers in
CSCs. B, Expression of cell surface markers in mesenchymal stem cells (MSCs). C, RT Real-time PCR data showed mRNA levels of cardiac specific
transcription factors in CSCs, MSCs and cardiomyocytes (isolated from adult mouse heart as a positive control). Mean 6 SEM, n=3 individual
experiments. UD: Undetectable.
doi:10.1371/journal.pone.0029246.g001
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protective factors are secreted from CSCs.
VEGF was not critical to CSC-mediated acute protection
following myocardial I/R injury
Next, we determined which molecule(s) from CSCs is
responsible for this acute protection following myocardial I/R
injury. Given that VEGF plays a critical role in stem cell-mediated
paracrine protection [7], we hypothesized that VEGF derived
from CSCs might play a role in CSC-mediated acute protection
following I/R injury. To verify this, siRNAs of VEGF and
scramble control were transfected into CSCs. After 2 days, VEGF
production in the transfected CSCs was measured. Interestingly,
although VEGF siRNA reduced CSC production of VEGF
(Fig. 3A), these transfected CSCs were still able to protect post-
ischemic myocardial function as scramble siRNA-transfected
CSCs did (Fig. 3B), indicating that CSC-derived VEGF may not
be critical to this acute protection.
Differentiated CSCs (DSCSs) did not protect cardiac
function in response to I/R
To further identify what component plays an important role in
CSC-mediated paracrine protection, we determined whether
DCSCs still possessed this acute protective effect. DCSCs were
obtained by culturing CSCs in cardiomyocyte differentiation
medium for 9–10 days. DCSCs exhibited decreased expression of
Sca-1, CD29 and CD44 by Flow cytometric assay (Fig. 4A). In
addition, higher mRNA levels of NKX2.5, Gata4 and Tbx5, as
well as cardiac a-MHC, MLC2v, cTnT and Troponin I were
observed in DCSCs compared to un-induced CSCs (Fig. 4B).
Furthermore, DCSCs showed increased protein levels of Gata4
and sarcomeric (SM) a-actin by Western blot analysis and
Immunofluorescent assay (Fig. 4C, D).
After identified their properties, the same amount of DCSCs
(0.1610
6 in 1 ml of perfusate) was injected into isolated mouse
hearts before ischemia. Interestingly, pretreatment with DCSCs
did not improve myocardial function following I/R as CSCs did.
Markedly decreased post-ischemic LVDP and +/2 dP/dt were
observed in the DCSC-treated group compared to CSC group
(Fig. 4E). Given size of cardiomyocytes being much larger than
that of stem cells [11,21,22], the differentiation process may result
in an enlarged size of DCSCs. Therefore, to obviate possible
coronary embolism by DCSC infusion that may limit blood flow,
exacerbating I/R-induced myocardial damage and consequent
deterioration of cardiac function, we further utilized DCSC CM.
Consistent with the result from infusion of DCSCs, pretreatment
with DCSC CM did not protect post-ischemic cardiac function as
Figure 2. CSC-derived paracrine protection in myocardial function following I/R. Left ventricular developed pressure (LVDP) recording
trace was shown during equilibration (Eq), global ischemia and reperfusion (A). Changes of LVDP and +/2 dP/dt following I/R in groups of CSC, MSC
and vehicle (B), and groups of CSC CM and media control (C). Mean 6 SEM, n=5–6/group, *p,0.05, **p,0.01, ***p,0.001 vs. vehicle or media
controls. CM: conditioned medium.
doi:10.1371/journal.pone.0029246.g002
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are secreted from CSCs, but not from DCSCs.
SDF-1 was a dominant paracrine factor in CSCs
To determine what protective paracrine factors are different
between CSCs and DCSCs, a cytokine antibody array was
performed on the cell culture media. Different patterns of
paracrine factor production were observed between CSCs and
DCSCs (Fig. 5A). Much higher levels of SDF-1, PAI-1, PTX-3
and IGFBP-9 were found in CSC CM, whereas greater
production of MMP-3 and VEGF existed in DCSC CM. Among
these, SDF-1 was the most abundant factor in CSC CM compared
to DCSC CM. We further confirmed that CSCs produced higher
levels of SDF-1 compared to DCSCs using ELISA (Fig. 5B). In
addition, CSCs expressed a 30-fold higher level of SDF-1
compared to cardiomyocytes (CSC 69.3611.2 ng/mg vs. Myo-
cyte 2.360.6 ng/mg) (Fig. 5C), suggesting that CSC differentiated
to cardiomyocytes would decrease SDF-1 production. Further-
more, with respect to the capacity of producing other well-studied
paracrine molecules, CSCs exhibited much lower mRNA and
protein levels of VEGF, HGF and IGF-1 than their SDF-1
expression (Fig. 6A, B). These results together indicated that SDF-
1 was a relatively abundant factor in CSCs.
Role of CSC-derived SDF-1 in acute protection following
I/R
We next investigated the role of CSC-derived SDF-1 in
modulating cardioprotection. SDF-1 has been shown to exert its
biological function through binding to its cognate receptor,
CXCR4, which is present in cardiac tissue [23]. Our recent
studies also confirmed that CXCR4 was expressed in isolated
rodent hearts [24,25]. Blockade of the SDF-1 receptor by
AMD3100 dramatically impaired CSC-mediated protection of
myocardial function to the levels seen in vehicle group and
significantly decreased post-ischemic recovery of LVDP and +/2
dP/dt compared to CSC CM group (Fig. 7). To verify this result,
we utilized SDF-1 siRNA-transfected CSCs. SDF-1 siRNA
decreased CSC production of SDF-1 by more than 80%, whereas
scramble siRNA did not affect CSC-secreted SDF-1(Fig. 8A).
Consistent with the result of AMD3100, a decrease in CSC
production of SDF-1 abolished CSC-protected myocardial
function following I/R, whereas scramble siRNA did not attenuate
CSC-improved myocardial function (Fig. 8B). These data suggest
that SDF-1 is a critical factor in CSC-mediated acute protection of
myocardial function.
To further study the role of CSC-derived SDF-1 in alleviation of
myocardial damage, we assessed lactate dehydrogenase (LDH)
levels in cardiac tissue after I/R. Greater myocardial damage from
I/R leads to higher levels of LDH in the coronary effluent and
lower remaining LDH in cardiac tissue. After I/R, higher levels of
LDH in cardiac tissue were observed in groups of CSCs and CSC
CM, implying less LDH released into coronary effluent and less
severe myocardial damage in these hearts (Fig. 9A). However,
using AMD3100 or SDF-1 siRNA resulted in lower levels of LDH
remaining in the myocardium, indicating more severe cardiac
damage. In addition, we observed that active caspase-3 levels were
lower in CSC- or CSC CM- pretreated groups versus vehicle
control after acute myocardial I/R, whereas blockade of SDF-1
receptor or reduction of SDF-1 release from CSCs increased
cardiac caspase-3 activity (Fig. 9B), suggesting that SDF-1 is able
to mediate acute protection in part through attenuation of cellular
injury in response to myocardial I/R.
Following I/R injury, reactive oxygen species was produced
in the heart. Hydrogen peroxide (H2O2), a reactive oxygen
Figure 3. Role of VEGF in CSC-mediated acute protection
following myocardial I/R injury. A, Production of VEGF was
determined in siRNA transfected CSCs by ELISA. Mean 6 SEM, N=3,
***p,0.001 vs. vehicle or scramble siRNA. B, VEGF siRNA transfection
did not attenuate CSC-improved myocardial function following I/R.
Mean 6 SEM, N=5–6/group, *p,0.01 vs. scramble siRNA and VEGF
siRNA, #p,0.05 vs. scramble siRNA only.
doi:10.1371/journal.pone.0029246.g003
SDF-1 in CSC-Protected Cardiac Function during I/R
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29246SDF-1 in CSC-Protected Cardiac Function during I/R
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29246metabolic by-product, plays an important role in regulating
oxidative stress-related states. Therefore, to elucidate the paracrine
effect of CSCs on myocardial oxidative stress, we determined
H2O2 production after I/R. We found that although there was a
trend of decreased H2O2 production in CSCs or CSC CM-
treated group, infusion of CSCs or CSC CM did not significantly
reduce myocardial H2O2 production following acute I/R
(Fig. 9C).
To determine whether CSC-secreted SDF-1 protects cardio-
myocytes against injury, CSC CM was applied to cardiomyocytes
(H9c2 cells, ATCC, Manassas, VA) subjected to hypoxia (1% O2)
with or without AMD3100. After 24-hr of hypoxia, the
supernatant was collected for an LDH assay and cell viability
was determined by Trypan-blue exclusion. CSC CM protected
cardiomyocytes from death following hypoxia as demonstrated by
greater cell survival and lower levels of LDH in the supernatant
compared to control (Fig. 9D). However, inhibition of SDF-1
receptor by AMD3100 neutralized this protection provided by
CSC CM, indicating that CSC-derived SDF-1 is able to directly
promote cardiomyocyte survival.
Inhibition of myocardial STAT3 impaired CSC-mediated
cardioprotection following I/R
Studies have demonstrated that SDF-1-induced activation of
Akt or STAT3 is involved in mediating cellular responses in a
variety of cells [23,26–28]. In addition, we have recently reported
that SDF-1 conducts acute protection through myocardial STAT3
signaling in response to global I/R injury [24]. Here, to investigate
by which pathway CSCs mediate acute protection in the heart
subjected to I/R, we examined myocardial activation of STAT3.
We observed that infusion of CSCs or CSC CM prior to ischemia
significantly increased STAT3 activation following I/R (Fig. 10A).
In addition, blockade of SDF-1 receptor or transfection of SDF-1
siRNA markedly decreased myocardial STAT3 activation
(Fig. 10B). To further identify the role of STAT3 pathway in
CSC-mediated acute protection in response to I/R, the STAT3
inhibitor-stattic was utilized. Inhibition of STAT3 significantly
impaired post-ischemic myocardial function in CSC-treated group
to a level seen in vehicle controls (Fig. 10C). Similarly, using stattic
reversed CSC-reduced cellular damage in the heart subjected to I/
R as exhibited by the level of cardiac LDH (Fig. 10D) and active
caspase-3 expression (Fig. 10E).
The role of Akt signaling in CSC-induced cardioprotecion
in response to acute I/R
To investigate whether the Akt pathway plays a role in CSC-
mediated acute protection in the heart subjected to I/R injury, we
determined myocardial Akt activation. We observed that pretreat-
ment with CSCs or CSC CM did not affect myocardial Akt
activation (Fig. 11A). In addition, using SDF-1 receptor blocker in
CSC CM or transfection of SDF-1 siRNA in CSCs did not change
myocardial levels of phosphorylated-Akt (Fig. 11B). These results
suggest that the Akt pathway is unlikely involved in mediating
CSC-derived paracrine protection. To further rule out the
contribution of Akt signaling in CSC-mediated acute protection,
we utilized LY294002, an inhibitor of the Akt pathway. We
observed that blockade of Akt signaling by using LY294002 did
not attenuate CSC-improved myocardial function in response to
acute I/R (Fig. 11C), further implying that CSC-induced
paracrine protection is not mediated through the Akt pathway
during I/R.
Post-ischemic infusion of CSCs or CSC CM in protection
of myocardial function
To determine paracrine effect of CSCs on cardioprotection in a
situation related to the clinical setting in which the ischemic
damage is already present, we injected CSCs post-ischemically.
However, we found that treatment of CSCs during the initiation of
reperfusion resulted in many cells washed out of the myocardium
by perfusion, and the cells stayed in the heart were not sufficient to
produce adequate amounts of paracrine factors for cardioprotec-
tion. Our results indicated that although a trend of improved
myocardial function was noticed in CSC-treated group following
Figure 4. Role of differentiated CSCs (DCSCs) in myocardial functional recovery following I/R. A, Expression of Sca-1, CD29 and CD44 in
DCSCs was determined by Flow cytometry assay. B, RT Real-time PCR analysis indicated transcription levels of cardiac specific transcription factors
and genes in DCSCs. C, Western blot assay demonstrated increased expression of Gata4 and sarcomeric (SM) a-actin in DCSCs compared to un-
induced CSCs. D, Expression of SM a-actin (green) and Gata4 (red) was observed in DCSCs by Immunofluoresence assay (Magnification 400X). Nucleus
was stained with DAPI (blue). Myocardial functional recovery at end of reperfusion was represented as % of equilibration (Eq) in groups treated with
vehicle, CSC and DCSC (E) or media control, CSC CM and DCSC CM (F). Mean 6 SEM, n=5–6/group, *p,0.01, **p,0.001 vs. Vehicle or Media C,
#p,0.01, ##p,0.001 vs. CSC or CSC CM. CM: conditioned medium.
doi:10.1371/journal.pone.0029246.g004
Figure 5. Determination of dominant paracrine factor(s) in
CSCs. A, Cytokine antibody array was performed in conditioned
medium (CM) from CSCs and DCSCs. Each number represented the fold
increase of cytokine expression compared to the negative control
(medium). B, CSC- and DCSC-secreted SDF-1 was determined in
supernatants by ELISA. C, The SDF-1 expression in CSCs and
cardiomyocytes was analyzed in cell lysates using ELISA. Mean 6
SEM, N=3–6/groups, ***p,0.001 vs. CSC. UD: Undetectable.
doi:10.1371/journal.pone.0029246.g005
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identify the contribution of paracrine effect of CSCs on
protection of myocardial function, we therefore infused CSC
CM post-ischemically. We observed that post-ischemic infusion of
CSC CM did significantly improve myocardial function as
indicated in Figure 12B, suggesting that CSC-derived paracrine
molecules are capable of inducing acute protection in a clinical-
related setting.
Figure 6. CSCs expressed much higher mRNA (A) and protein levels (B) of SDF-1 compared to production of VEGF, HGF and IGF-1.
Mean 6 SEM, N=4 individual experiments, ***p,0.001 vs. SDF-1.
doi:10.1371/journal.pone.0029246.g006
Figure 7. CSC-derived SDF-1 in mediating acute protection following I/R. A, Changes of LVDP and +/2 dP/dt following I/R in groups of
media control and CSC CM with or without AMD3100, an inhibitor of the SDF-1 receptor. B, Myocardial functional recovery at end of reperfusion was
shown as % of Eq (equilibration). Mean 6 SEM, n=5–6/group, *p,0.05, **p,0.01, ***p,0.001. CM: conditioned medium.
doi:10.1371/journal.pone.0029246.g007
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In order to understand the paracrine action of CSCs in an
ischemic enviroment, we conducted the present study which
provided the initial evidence showing that CSC-derived SDF-1
mediated acute cardioprotection following I/R injury. Here, we
reported that CSCs were capable of carrying on paracrine
protection like MSCs did. SDF-1 was identified as one of the
abundant paracrine factors in CSCs and played a critical role in
CSC-mediated acute protection likely through STAT3 pathway
following I/R.
The mammalian heart was originally thought to be a terminally
differentiated organ without endogenous regenerative propeties
after cardiac injury. However, accumulating studies have recently
demonstrated that adult hearts contain a small number of cells
expressing stem cell markers (Sca-1, c-Kit, MDR-1, etc.)
[8,12,14,17]. Such cells can differentiate into functional cardio-
myocytes in vivo and in vitro. Transplantation of CSCs into
infarcted myocardium has improved cardiac function and
myocardial remodeling [8,12,19]. Therefore, the use of CSCs is
promising for myocardial regeneration in the treatment of MI.
However, the time period of at least several days is required for the
CSC differentiation process. Before they develop into functional
cardiomyocytes for repair purposes, CSCs may secret some
molecules which are protective against myocardial injury. In fact,
it is evident that paracrine factors play a major role in noncardiac
stem cell-mediated cardioprotection after MI. However, the
paracrine mechanism remains largely unclear after transplantation
of CSCs into the ischemic heart. Herein, we observed that
treatment of CSCs or CSC CM prior to ischemia significantly
improved myocardial function very soon after I/R. In addition, in
a setting related to the clinical situation, infusion of CSC CM
during the initiation of reperfusion also protected myocardial
function. These findings indicate that CSCs are capable of
producing paracrine factors to mediate acute cardioprotection.
To date, it has been documented that many growth factors and
cytokines derived from stem cells improve myocardial function,
promote cell survival, advance ventricular remodeling and
decrease tissue damage after myocardial ischemia. Among these,
VEGF is a critical factor in angiogenesis and has been shown to
facilitate stem cell paracrine protection in the ischemic myocar-
dium [1,29,30]. Genetically modified bone marrow cells overex-
pressing VEGF are even more effective for cardioprotection [29].
In addition, our previous study has demonstrated that lowering
VEGF levels alone by using VEGF siRNA in MSCs neutralizes
MSC-induced protection of myocardial function following acute
I/R [7]. Therefore, to elucidate the effect of CSC-derived VEGF
on acute protection, we suppressed VEGF production in CSCs
using VEGF siRNA. However, these CSCs were still able to
improve myocardial function as scramble siRNA-transfected-
CSCs did following I/R, indicating that VEGF is not critical to
CSC-mediated acute protection.
We then asked the question whether CSCs differentiated to
cardiomyocyte phenotype were still capable of conferring
paracrine protection following I/R. We observed that pretreat-
ment with DCSCs or DCSC CM did not protect the ischemic
Figure 8. Decreased SDF-1 in CSC-mediated cardioprotection
following acute I/R injury. A, Production of SDF-1 was determined in
siRNA transfected CSCs by ELISA. Mean 6 SEM, N=4, ***p,0.001 vs.
Vehicle and Scramble siRNA. B, Changes of LVDP and +/2 dP/dt
following I/R in groups of vehicle and CSCs transfected with specific
siRNAs. Mean 6 SEM, N=5–6/group, *p,0.01 vs. Vehicle or SDF-1
siRNA.
doi:10.1371/journal.pone.0029246.g008
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CSCs, but not DCSCs. Therefore, through direct comparison of
the protein expression profiles of CSCs and DCSCs, SDF-1 was
identified as one of the abundant paracrine factors in CSCs. In
addition, CSCs secreted a larger amount of SDF-1 when
compared to production of VEGF, HGF and IGF-1. In fact,
previous research has already addressed that production of VEGF
and HGF was not dominant in cardiac progenitor cells [19,20].
Cardiosphere-derived cells have been shown to be incapable of
producing HGF and IGF-1 [18].
Notably, when MSC-secreted VEGF dropped to the level of
around 200 pg/ml by VEGF siRNA transfection, these MSCs did
not provide protection of myocardial function following I/R injury
[7]. In the current study, we have observed that CSCs and DCSCs
produced VEGF at the level of ,100 pg/ml and ,200 pg/ml,
respectively. This level of VEGF did not offer cardioprotection to
DCSCs in response to I/R. In contrast, VEGF siRNA-transfected
CSCs were still able to improve post-ischemic myocardial
function. Taking them collectively, therefore, these findings
suggest that a certain quantity of VEGF produced from stem
cells is likely required to mediate protection. However, it still
remains unclear whether the magnitude of cardioprotective effects
is dependent on the quantity of other cytokines secreted from
CSCs. In this regard, we determined whether abundantly secreted
SDF-1 is critical to mediating CSC-induced acute cardioprotec-
tion. Herein, blockade of the SDF-1 receptor in the heart
significantly attenuated CSC-induced paracrine protection follow-
ing myocardial I/R. In addition, when SDF-1 expression in CSCs
was downregulated by SDF-1 siRNA, pretreatment of CSCs did
not improve post-ischemic cardiac function. Therefore, our data
clearly indicate that SDF-1 is critical to CSC-mediated paracrine
protection in hearts subjected to I/R.
Although the beneficial effects of SDF-1 have been mainly
attributable to mobilization and recruitment of stem cells into an
infarcted heart, recent studies have indicated that direct delivery
of SDF-1 into the myocardium improved post-ischemic cardiac
function within 24 hours of injury [26]. This favorable effect is
likely due to preservation of myocardial tissue rather than
through recruitment of stem cells [26]. In fact, SDF-1 has been
shown to promote cell survival in a variety of cells including
cardiomyocytes [23,26]. In this study, our brief experiment
period (a total of 65 minutes for I/R) limited the observation in
the end-point of an influence of CSC-derived SDF-1 on
programmed cell death after I/R. However, we did observe that
CSCs or CSC CM decreased active caspase-3 levels and
attenuated myocardial damage following I/R. In addition,
blockade of the SDF-1 receptor in the heart or downregulated
SDF-1 expression in CSCs abolished this protection in the
myocardium. Furthermore, CSC CM protected cardiomyocytes
from cell death following hypoxia, and inhibition of SDF-1
receptor neutralized this protection. These findings indicate that
CSC-derived SDF-1 is able to mediate cardioprotection through
alleviation of myocardial damage.
SDF-1 has been shown to upregulate Akt activation in
cardiomyocytes and thus to promote cell survival after MI
[23,26]. Given that SDF-1 is a dominant paracrine factor in
CSCs, it was postulated that CSC-induced paracrine protection
may be mediated via increased Akt activation. However, in this
study, infusion of CSCs or CSC CM did not upregulate cardiac
Akt activation. In addition, neither blockade of SDF-1 receptor
nor reduced SDF-1 levels in CSCs by transfection of specific SDF-
1 siRNA downregulated myocardial activation of Akt after I/R.
On the contrary, increased myocardial STAT3 activition was
observed in CSC or CSC CM-treated hearts after I/R here. In
addition, downregulation of SDF-1 pathway by inhibition of the
SDF-1 receptor or transfection of SDF-1 siRNA in CSCs reduced
cardiac activation of STAT3. In fact, it has been noted that
CXCR4 contains two domains which are involved in regulating
Figure 9. CSC-derived SDF-1 in the attenuation of cellular
injury. A, Remaining LDH levels in cardiac tissue were determined after
I/R. B, Western blot analysis indicated cleaved caspase-3 levels after I/R.
Shown is representative immunoblots in each groups (one lane/group).
Bar graph represents relative levels of Caspase-3 P20 (% of GAPDH). C,
Myocardial hydrogen peroxide (H2O2) production was analyzed after I/
R. A–C: Mean 6 SEM, N=4–5/group, *p,0.05, **p,0.01 vs. Vehicle. D,
Cardiomyocyte (H9c2) viability and LDH levels in supernatant were
determined after 24-hr of hypoxia in groups of vehicle and CSC CM with
or without AMD3100. Mean 6 SEM, N=3, *p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0029246.g009
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CXCR4 is able to trigger STAT3 activation, which then regulates
cellular function in a variety of cells [27,28]. Our recent study has
also demonstrated that acute administration of SDF-1 prior to
ischemia protects myocardial function through increased STAT3
activation following I/R injury [24]. In addition, SDF-1-increased
STAT3 activation has been observed to improve cell growth and
inhibit apoptosis [31,32]. STAT3 is a protective factor in the heart
and its activation mediates several down-stream signals, including
upregulation of anti-apoptotic protein Bcl-2 or Bcl-xL [33–35],
induction of heat shock proteins [36–38], production of angiogenic
factors [39], and reduction of inflammatory cytokines [39–41].
Our findings here suggest that CSC-derived SDF-1 induces acute
cardioprotection through upregulation of STAT3 following
myocardial I/R. Furthermore, inhibition of STAT3 activity
significantly impaired CSC-derived paracrine protection, implying
Figure 10. Myocardial STAT3 in CSC-mediated acute cardioprotection following I/R. A, Myocardial activation of STAT3 was determined in
groups of Vehicle, CSCs, media control and CSC CM after I/R by Western blot assay. B, AMD3100 or SDF-1 siRNA neutralized CSC-induced STAT3
activation compared to their counterparts. Representative immunoblots of p-STAT3 and T-STAT3 were shown (one lane/group) and bar graph
represents relative levels of p-STAT3/T-STAT3 ( %) in A and B. C, Stattic abolished CSC-mediated acute protection as demonstrate by unimproved
LVDP and +/2 dP/dt following I/R. D. Remaining LDH in myocardial tissue after I/R. E. Cardiac caspase-3 levels were determined in hearts treated with
vehicle, stattic and CSC+stattic after I/R by Western blot. Shown are representative immunoblots (2 lanes/group). Results are Mean 6 SEM, N=4–5/
group, *p,0.05 vs. vehicle or media control.
doi:10.1371/journal.pone.0029246.g010
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cardioprotection.
In this study, the Langendorff model was employed to
characterize the paracrine effects of CSCs on myocardial function
following global I/R. This isolated heart perfusion system obviates
confounding effects of systemic actions including the effects of
SDF-1on mobilization and recruitment of exogenous stem cells
into the injured heart. In addition, this model has direct clinical
relevance as global myocardial ischemia is employed during
cardiac operations, such as cardiopulmonary bypass and cardio-
plegic arrest. However, further investigations are required using an
in vivo MI model to completely understand the long-term effects
of CSC-derived paracrine factors on angiogenesis, tissue regener-
ation and myocardial remodeling.
Materials and Methods
Ethics Statement
All animal studies conformed to the "Guide for the Care and
Use of Laboratory Animals" (NIH publication No. 85–23,
revised 1996). The protocols were reviewed and approved by
the Indiana Animal Care and Use Committee of Indiana
University.
Preparation of cells and conditioned medium
Mouse CSCs were isolated from 6–7-week-old C57BL mice
(Jackson Laboratories, Bar Harbor, ME) using a CSC isolation
kit (Millipore, Billerica, MA) and were cultured in CSC
maintenance medium (Millipore). After 2 weeks, the medium
was changed to Iscove’s Modified Dulbecco’s Medium (GIBCO
Invitrogen, Carlsbad, CA) with 10% fetal bovine serum and 1%
pen-strep (IMDM completed medium) [9]. CSCs were measured
for characteristics after one month. Differentiated CSCs (DCSCs)
were obtained by culturing CSCs in cardiomyocyte differentia-
tion medium (Millipore) for 9–10 days. Adult mouse cardiomy-
ocytes were isolated from 8–10-week-old C57BL mouse hearts
using a nonperfusion cardiomyocyte isolation system (Cellutron,
Baltimore, MD). MSCs were isolated from 8–10-week-old
C57BL mouse bone marrow and cultured as previously described
[6,42].
Figure 11. The Akt pathway in CSC-induced cardioprotection following I/R. A, Western blot assay revealed myocardial Akt activation in
groups of Vehicle, CSCs, media control and CSC CM after I/R. B, The use of AMD3100 in CSC CM or SDF-1 siRNA in CSCs did not change myocardial Akt
activation. Shown are representative immunoblots of p-Akt and T-Akt (one lane/group), and densitometry data of p-Akt represented as % of T-Akt. C,
Inhibition of the Akt signaling by LY294002 did not affect CSC-improved post-ischemic LVDP, +dP/dt and –dP/dt. Results are mean 6 SEM, n=4-6/
group, *p,0.05, **p,0.01 vs. control or LY294002 alone at the corresponding time point.
doi:10.1371/journal.pone.0029246.g011
SDF-1 in CSC-Protected Cardiac Function during I/R
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e29246CSCs and DCSCs (1610
6) were plated in 75-cm flasks. After
incubation for 6 hours in IMDM completed medium, cells were
washed with PBS 2 times and cultured in 10 ml of serum-depleted
IMDM. 24 hours later, supernatant was collected as conditioned
medium (CM).
Isolated mouse heart preparation (Langendorff Model)
A Langendorff perfusion system was utilized in isolated mouse
hearts that were subjected to the same I/R protocol: 15-min
equilibration followed by 25-min global ischemia (37uC) and 40-
min reperfusion. Mouse hearts were isolated as our previously
described [43–47]. Briefly, mice were anesthetized using isoflurane
and heparinized (500 U i.p.), and hearts were rapidly excised via
median sternotomy and placed in 4uC Krebs-Henseleit solution.
The aorta was cannulated and the heart was perfused in the
isovolumetric Langendorff mode (70 mmHg) and paced at
420 bpm/min except during ischemia. Data were continuously
recorded using a PowerLab 8 preamplifier/digitizer (AD Instru-
ments Inc., Milford, MA). The maximal positive and negative
values of the first derivative of pressure (+ dP/dt and -dP/dt) were
calculated using PowerLab software.
A total of 87 male C57BL mice (9–10-week-old) were randomly
divided into (n=5–6 hearts/group): 1) vehicle; 2) CSCs; 3) MSCs;
4) media control; 5) CSC CM; 6) scramble siRNA-transfected
CSCs; 7) VEGF siRNA-transfected CSCs; 8) DCSCs; 9) DCSC
CM; 10) Media control+AMD3100, a specific inhibitor of SDF-1
receptor (CXCR4), 5 mg/ml; 11) CSC CM+AMD 3100; 12) SDF-
1 siRNA-transfected CSCs; 13) Stattic, an inhibitor of STAT3
activation, 20 mM; 14) CSCs+Stattic; 15) Media control+
Ly294002, a specific inhibitor of Akt pathway, 2.5 mM; 16) CSC
CM+Ly294002. Cells (0.1610
6 in 1 ml of perfusate), CM (1.5 ml)
or vehicle was infused into the according isolated mouse hearts
through a port above the aortic root within 1 minute immediately
before ischemia. The drugs were infused into the isolated mouse
hearts within 5 minutes before infusion of cells or CM. All doses of
cells and drugs were chosen based on our preliminary studies and
previous literature [6,23,24,48]. In addition, concerning that the
ischemic damage already occurs in the clinical setting, we further
infused CSCs (0.1610
6 in 1 ml of perfusate) or CSC CM (1.5 ml)
into ischemic hearts during the initiation of reperfusion to identify
paracrine effect of CSCs on cardioprotection in a clinical point of
view.
Figure 12. Post-ischemic infusion of CSCs or CSC CM in protection of myocardial function in response to I/R. LVDP and +/2 dP/dt
following I/R in groups of CSC and control (A), and groups of CSC CM and vehicle (B). Mean 6 SEM, n=5–6/group, *p,0.001 vs. vehicle at the
corresponding time point. CM: conditioned medium.
doi:10.1371/journal.pone.0029246.g012
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FITC-conjugated anti-CD45, PE-conjugated anti-Sca-1, CD29,
CD31, CD44, CD45, and APC-conjugated CD117 (c-Kit)
antibodies (Abs) were purchased from eBioscience (San Diego,
CA) and BD Biosciences (San Jose, CA). The standard immuno-
fluoresescent staining method was utilized and the percentage of
cells expressing each cell surface antigen was analyzed by a
FACSCalibur flow cytometer (BD Biosciences).
RT Real-time PCR
Total RNA was extracted by using RNA STAT-60 (TEL-
TEST, Friendswood, TX). 0.1 mg of total RNA was subjected to
cDNA synthesis using cloned AMV first-strand cDNA synthesis kit
(Invitrogen). Primer sequences are shown in Table 1. SYBR green
real-time PCR amplification was performed on a 7300 real-time
PCR system (Applied Biosystems, Foster City, CA).
Western blot
Cells and heart tissues were lysed in cold RIPA buffer (Sigma,
Saint Louis, MO). The protein extracts (10–30 mg) were
subjected to electrophoresis on a 4–12% precise protein gel
(Invitrogen) and transferred to a nitrocellulose membrane. The
membranes were incubated with the following primary Abs:
Gata4 (Santa Cruz Biotechnology Inc., Santa Cruz, CA),
Sarcomeric (SM) a-actin (Sigma), Akt, phosphor-Akt (p-Akt),
STAT3, phosphor-STAT3 (p-STAT3) (Cell Signaling Technol-
ogy, Beverly, MA), caspase-3 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) and GAPDH (Biodesign International, Saco,
Maine), followed by horseradish peroxidase-conjugated goat anti-
rabbit or anti-mouse secondary Ab and detection using Super-
Signal West Pico stable peroxide solution (Pierce, Rockford, IL).
Films were scanned using an Epson Perfection 3200 Scanner
(Epson America, Long Beach, CA).
Immunofluorescent staining
The cells grown on the chamber slide system were fixed and
stained with anti-Gata4 and anti-SM a-actin Abs using a standard
immunohistochemistry protocol followed by incubation with
Texas red-conjugated anti-rabbit or Fluorescein-conjugated anti-
mouse Abs (Vector Laboratory, Burlingame, CA). DAPI was used
for nuclear staining. Cell morphology and fluorescence were
examined under an inverted fluorescence microscope (Nikon
TE2000U, Nikon, Melville, NY). Images were digitalized with
QCapture (QImaging, Surrey, BC).
Cytokine Ab array
Cytokine secretion was determined in conditioned medium
from CSCs and DCSCs by using a cytokine Ab array according to
the manufacturer’s instructions (R&D Systems Inc., Minneapolis,
MN). The signals were detected by using SuperSignal West Pico
stable peroxide solution (Pierce). Signal densities were compared
using TotalLab software (Nonlinear USA, Inc., Durham NC).
siRNA transfection
VEGF siRNA [7], SDF-1 siRNA and scrambled-control siRNA
were purchased from Dharmacon (Lafayette, CO). Lipofectamine
2000 (Invitrogen) was used to transfect these siRNAs into CSCs
based on a standard transfection method. CSCs were plated in 12-
well plate at 0.5610
5/well/ml on day 1. On day 2, cells were
transfected with according siRNAs using standard procedure.
After 1 day of transfection (day 3 in culture), complexes containing
siRNA were washed out, normal IMDM medium was added, and
the cells were allowed to incubate for an additional 2 days. On day
5, the supernatant was collected for the measurement of VEGF
and SDF-1 by using ELISA, and CSCs were harvested for
Langendorff experiments.
ELISA
The supernatants collected from cell culture were measured for
production of SDF-1, VEGF, HGF and IGF-1 using according
ELISA kit (R&D). In addition, protein levels of SDF-1 were also
determined between CSCs and cardiomyocytes that were isolated
from adult mouse hearts and cultured for 2 hours in vitro.
Measurement of cell/tissue damage
Cell viability was analyzed by Trypan-blue exclusion and the
fraction of blue cells was quantified by light microscopy. LDH
activity was assessed to determine the extent of cellular injury
using a Cytotoxicity Detection Kit (Roche Diagnostics Corpora-
tion, Indianapolis, IN).
Myocardial oxidative stress
Heart samples were prepared as described above in the section
of Western blot. Oxidative stress after I/R was determined by
myocardial H2O2 production using a Red Hydrogen Peroxide
Assay kit (Enzo Life Sciences International, INC., Plymouth
Meeting, PA) according to the manufacturer’s instructions.
Presentation of data and statistical analysis
All reported values are mean 6 SEM. Data were compared
using two-way analysis of variance (ANOVA) with post-hoc
Bonferroni test or Student’s t-test. A probability value of less than
0.05 was considered statistically significant.
Table 1. PCR primers.
Genes Forward 59-39 Reverse 59-39
NKX2.5 AAAAGAGCTGTGCGCGCTGCAGAAG
TAGACCTGCGCCTGCGAGAAGAGCAC Gata4
CACCCCAATCTCGATATGTTTGATGAC
ATTGCACAGGTAGTGTCCCGTCCCATC MEF2c
CACGATGCCATCAGTGAATCAAAGG
CTTGTCCTGGTAAAGTAGGAGTTGC Tbx5
ACCAGAATCACAAGATCACACAGCTG
CTCTTTACTTTGCATCCGAGACATCC a-MHC
ACCAGAGTTTGAGTGACAGAATGACG
TGGGCCTCTAGGCGTTCCTTCTCTG MLC2v
GAGAAACTTAAAGGGGCTGATCCTG
AGCATCTCCCGGACATAGTCAGCCTTC cTnT
AAACCCAAGCCCAGCAGGCTCTTCATG
CTTCCTGTGGATGTCATCAAAGTCCAC Tnni3
AAGAGCTTCAGGACTTATGCCGACAGC
GTCAGATCTGCAATCTCAGTGATGTTC SDF-1
TCTGCATCAGTGACGGTAAACCAG CTTGACGTTGGCTCTGGCGATGTG
VEGF ACATCACCATGCAGATCATGCGGATC
TCACATCTGCTGTGCTGTAGGAAGC HGF
CTTTACGTTCACTTGCAAGGCCTTC
CTCCACTTGACATACTATTGAAAGG IGF-1
GCTTTTACTTCAACAAGCCCACAGG
AAGCAACACTCATCCACAATGCCTG RPL7
TTTGCCCTGAAGACACTTCGAAAGG
TTCCTTGCCATCCTGGCCATCCGAATC b-actin
AACCGTGAAAAGATGACCCAGATCATG
ACAACACAGCCTGGATGGCTACGTAC
doi:10.1371/journal.pone.0029246.t001
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